Skip to main content

Table 3 Associations of tumor characteristics with Parkinson’s disease gene mRNA relative expression in NSCLC

From: Status of the Parkinson’s disease gene family expression in non-small-cell lung cancer

Tumor characteristics

n (%)

PARK1/4 (SCNA)

 

PARK2(Parkin)

 

PARK5(UCHL-1)

 

PARK6(PINK1)

 

PARK7(DJ-1)

 

PARK8(LRRK2)

 

PARK9(ATP13A2)

 

PARK15(FBXO7)

 

GBA

 
  

Means ± SD

P

 

Means ± SD

P

 

Means ± SD

P

 

Means ± SD

P

 

Means ± SD

P

 

Means ± SD

P

 

Means ± SD

P

 

Means ± SD

P

 

Means ± SD

P

 

Overall

114 (100.00%)

1.475 ± 1.088

  

3.177 ± 3.646

  

18.375 ± 15.551

  

5.465 ± 4.949

  

2.773 ± 2.336

  

2.272 ± 2.350

  

8.356 ± 7.402

  

1.956 ± 1.783

  

5.936 ± 4.328

  

Gender

                            

 Male

72 (63.16%)

1.499 ± 1.099

  

3.095 ± 3.974

  

18.349 ± 16.095

  

5.566 ± 4.993

  

2.638 ± 2.079

  

2.336 ± 2.357

  

8.329 ± 7.751

  

2.207 ± 1.938

  

6.472 ± 4.709

  

 Female

42 (39.84%)

1.433 ± 1.079

.755a1

 

3.317 ± 3.044

.756a1

 

18.419 ± 14.760

.982a1

 

5.291 ± 4.927

.776a1

 

3.005 ± 2.733

.422a1

 

2.161 ± 2.362

.703a1

 

8.401 ± 6.852

.960a1

 

1.524 ± 1.398

.500a2

 

5.016 ± 3.443

.147a2

 

Histology

                            

 Adenocarcinoma

64 (56.14%)

1.584 ± 1.080

  

4.900 ± 4.200

  

18.383 ± 14.360

  

5.422 ± 5.595

  

3.085 ± 2.710

  

2.346 ± 2.241

  

8.904 ± 7.890

  

2.125 ± 1.945

  

6.857 ± 4.274

  

 Squamous cell carcinoma

50 (44.86%)

1.367 ± 1.116

.303b1

 

1.202 ± 1.043

.000b2

 

18.784 ± 17.247

.894b1

 

5.436 ± 3.857

.988b1

 

2.410 ± 1.823

.005b1

 

1.901 ± 1.871

.274b1

 

7.557 ± 6.534

.337b1

 

1.775 ± 1.617

.311b1

 

5.642 ± 3.733

.282b1

 

Tumor stage

                            

 Stage I

36 (31.58%)

1.723 ± 1.371

.280c1

I–II

5.403 ± 5.442

.040c2

I–II

22.808 ± 18.141

.410c2

I–II

7.404 ± 6.642

.995c1

I–II

4.074 ± 3.377

.003c2

I–II

1.631 ± 1.391

.040c2

I–II

9.608 ± 9.410

.427c2

I–II

3.240 ± 2.546

.070c2

I–II

6.440 ± 5.055

.450c1

I–II

 Stage II

53 (46.49%)

1.457 ± 0.936

.176c1

II–III

2.217 ± 1.783

.598c1

II–III

14.625 ± 11.716

3.27c2

II–III

5.362 ± 4.101

.010c2

II–III

1.894 ± 0.743

.105c2

II–III

3.306 ± 2.880

.000c2

II–III

6.626 ± 5.645

.180c1

II–III

1.567 ± 0.818

.000c2

II–III

5.700 ± 4.131

.098c1

II–III

 Stage III

25 (21.93%)

1.155 ± 0.854

.720c1

I–III

2.001 ± 1.278

.130c1

I–III

19.939 ± 17.271

.538c2

I–III

2.891 ± 1.406

.003c2

I–III

2.765 ± 1.904

.215c2

I–III

1.002 ± 1.904

.100c2

I–III

10.198 ± 6.880

.790c1

I–III

0.930 ± 0.398

.000c2

I–III

5.714 ± 3.663

.542c1

I–III

  1. I–II means the compare between stages I and II, II–III means the compare between stages II and III, I–III means the compare between stages I and III
  2. a: Test for equality of medians between different gene relative expression and different sex: a1two-sided Student’s t-test; a2two-sided Wilcoxon rank sum test
  3. b: Test for equality of medians between different gene relative expression and different tumor histology: b1two-sided Student’s t-test; b2two-sided Wilcoxon rank sum test
  4. c: Test for equality of medians between different gene relative expression and different tumor stage: c1two-sided Student’s t-test; c2two-sided Wilcoxon rank sum test
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us